2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1512

Incidence of Co-Morbid Autoimmune Diseases in Patients with Rheumatoid Arthritis
Abstract Number: 1513

Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients
Abstract Number: 1514

Incidence and Risk Factors of Malignancy in a Cohort of Rheumatoid Arthritis Patients from Singapore
Abstract Number: 1515

Accounting for Rheumatoid Arthritis in the Determination of 10 Year Cardiovascular Risk
Abstract Number: 1516

Quality Improvement in Elderly Patients with Rheumatoid Arthritis: Pharmacotherapy and Identification of Cognitive Dysfunction
Abstract Number: 1518

Relationship Between Estimated Sodium and Potassium Intake with Blood Pressure and Inflammatory Markers in Patients with Rheumatoid Arthritis
Abstract Number: 1519

Pleuropulmonary Manifestations in Rheumatoid Arthritis Patients
Abstract Number: 1520

Safety, Clinical and Immunologic Effectiveness of the Live Zoster Vaccine Administered to Patients Receiving Anti-TNF Biologics
Abstract Number: 1521

Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Abstract Number: 1522

Correlation of Oxidized Low Density Lipoprotein Levels with Carotid Intima Media Thickness in Rheumatoid Arthritis Patients
Abstract Number: 1523

Ischemia Modified Albumin Levels in Rheumatoid Arthritis
Abstract Number: 1524

Evaluation of Changes in Cardiovascular Risk Factors Among Patients with RA Prescribed Biologic Dmards
Abstract Number: 1525

Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Abstract Number: 1526

Employment and Quality of Life Among Patients with Rheumatoid Arhtritis in Four Latin-American Countries
Abstract Number: 1527

Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].